Pro Vise Management Group, LLC Amgen Inc Transaction History

Pro Vise Management Group, LLC

$1.14 Billion
Q4 2024

A detailed history of Pro Vise Management Group, LLC transactions in Amgen Inc stock. As of the latest transaction made, Pro Vise Management Group, LLC holds 16,220 shares of AMGN stock, worth $5.17 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares

16,220

Previous 18,721 13.36%

Holding current value

$5.17 Million

Previous $6.03 Million 29.92%

% of portfolio

0.37%

Previous 0.48%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	SELL	$258.78 - $328.31 $647,208 - $821,103	-2,501 Reduced 13.36%	16,220 $4.23 Million
Q3 2024 Nov 12, 2024	SELL	$309.38 - $337.38 $47,335 - $51,619	-153 Reduced 0.81%	18,721 $6.03 Million
Q2 2024 Aug 12, 2024	SELL	$262.75 - $319.31 $94,852 - $115,270	-361 Reduced 1.88%	18,874 $5.9 Million
Q1 2024 May 09, 2024	SELL	$268.87 - $324.56 $590,707 - $713,058	-2,197 Reduced 10.25%	19,235 $5.47 Million
Q4 2023 Feb 09, 2024	SELL	$255.7 - $288.46 $97,421 - $109,903	-381 Reduced 1.75%	21,432 $6.17 Million
Q3 2023 Nov 08, 2023	SELL	$218.65 - $271.46 $72,810 - $90,396	-333 Reduced 1.5%	21,813 $5.86 Million
Q2 2023 Aug 24, 2023	BUY	$214.27 - $253.37 $47,353 - $55,994	221 Added 1.01%	22,146 $4.92 Million
Q1 2023 May 05, 2023	SELL	$225.79 - $275.2 $128,022 - $156,038	-567 Reduced 2.52%	21,925 $5.3 Million
Q4 2022 Feb 09, 2023	BUY	$229.03 - $291.01 $419,124 - $532,548	1,830 Added 8.86%	22,492 $5.91 Million
Q3 2022 Nov 09, 2022	BUY	$224.46 - $253.15 $520,298 - $586,801	2,318 Added 12.64%	20,662 $4.66 Million
Q2 2022 Aug 08, 2022	BUY	$230.71 - $256.74 $683,363 - $760,463	2,962 Added 19.26%	18,344 $4.46 Million
Q1 2022 Apr 27, 2022	BUY	$219.27 - $242.57 $761,524 - $842,445	3,473 Added 29.16%	15,382 $3.72 Million
Q4 2021 Jan 18, 2022	SELL	$198.88 - $227.6 $112,764 - $129,049	-567 Reduced 4.54%	11,909 $2.68 Million
Q3 2021 Oct 20, 2021	BUY	$212.27 - $248.7 $259,393 - $303,911	1,222 Added 10.86%	12,476 $2.65 Million
Q2 2021 Aug 06, 2021	BUY	$233.58 - $259.14 $54,190 - $60,120	232 Added 2.1%	11,254 $2.74 Million
Q1 2021 Apr 22, 2021	SELL	$221.91 - $258.6 $1,553 - $1,810	-7 Reduced 0.06%	11,022 $2.74 Million
Q4 2020 Jan 19, 2021	BUY	$216.38 - $257.67 $4,976 - $5,926	23 Added 0.21%	11,029 $2.54 Million
Q3 2020 Oct 26, 2020	SELL	$234.65 - $260.95 $95,502 - $106,206	-407 Reduced 3.57%	11,006 $2.8 Million
Q2 2020 Aug 07, 2020	SELL	$197.81 - $242.74 $126,202 - $154,868	-638 Reduced 5.29%	11,413 $2.69 Million
Q1 2020 May 07, 2020	SELL	$182.24 - $241.7 $34,807 - $46,164	-191 Reduced 1.56%	12,051 $2.44 Million
Q4 2019 Feb 11, 2020	BUY	$189.21 - $243.2 $69,061 - $88,768	365 Added 3.07%	12,242 $2.95 Million
Q3 2019 Nov 13, 2019	BUY	$174.11 - $208.62 $70,340 - $84,282	404 Added 3.52%	11,877 $2.3 Million
Q2 2019 Aug 09, 2019	SELL	$166.7 - $195.41 $6.49 Million - $7.6 Million	-38,906 Reduced 77.23%	11,473 $2.11 Million
Q1 2019 May 13, 2019	SELL	$180.87 - $203.88 $365,538 - $412,041	-2,021 Reduced 3.86%	50,379 $9.57 Million
Q4 2018 Feb 13, 2019	SELL	$178.4 - $208.25 $298,820 - $348,818	-1,675 Reduced 3.1%	52,400 $10.2 Million
Q3 2018 Nov 05, 2018	SELL	$185.29 - $208.89 $113,026 - $127,422	-610 Reduced 1.12%	54,075 $11.2 Million
Q2 2018 Aug 13, 2018	BUY	$166.05 - $186.51 $112,914 - $126,826	680 Added 1.26%	54,685 $20.2 Million
Q1 2018 May 09, 2018	SELL	$169.43 - $198.0 $5,930 - $6,930	-35 Reduced 0.06%	54,005 $9.21 Million
Q4 2017 Feb 07, 2018	BUY	$168.79 - $188.59 $170,984 - $191,041	1,013 Added 1.91%	54,040 $9.4 Million
Q3 2017 Nov 08, 2017	BUY	$167.29 - $191.0 $8.87 Million - $10.1 Million	53,027	53,027 $9.89 Million

Others Institutions Holding AMGN

# of Institutions

3,179

Shares Held

419M

Call Options Held

8.25M

Put Options Held

6.39M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Vise Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Vise Management Group, LLC with notifications on news.

Account

Pro Vise Management Group, LLC Amgen Inc Transaction History